Hepatitis Test Solution/Diagnosis Market

The global hepatitis test solution/diagnosis market is valued at 2.54 billion in 2017 and expected to grow at CAGR of 4.9% to USD 3.37 billion by 2023 during the forecast period.
This market is primarily driven by factors such as the high burden of hepatitis worldwide, increasing number of blood transfusions and donations, benefits offered by PoC instruments & kits, and awareness initiatives
The ELISA segment is expected to account for the largest share of the global hepatitis test solution/diagnosis market, by technology. The large share of ELISA is mainly driven by the wide acceptance of this test in clinical practices to diagnose hepatitis.
North America is expected to account for the largest share of the global hepatitis test solution/diagnosis market. The large share of the North America region is mainly attributed to factors such as the developed healthcare systems in the US and Canada, rising adoption of advanced technologies, and the presence of a large number of leading national clinical laboratories.
The key players in the hepatitis test solution/diagnosis market are Roche (Switzerland), Abbott Laboratories (US), Bio-Rad (US), Siemens (Germany), DiaSorin (Italy), QIAGEN (Netherlands), Danaher (US), bioMérieux (France), and Grifols (Spain).

Hepatitis test solution/diagnosis Market, by Disease type

Hepatitis B
Hepatitis C
Other Disease type

Hepatitis test solution/diagnosis Market, by Technology

ELISA
Rapid Diagnostics test
PCR
INAAT
Other Technologies

Hepatitis test solution/diagnosis Market, by End User

Hospitals & Diagnostics Labs
Blood Banks
Other end user